Enable Medicine

Enable Medicine is a biotechnology startup that aims to revolutionize the field by providing spatial and multimodal insights powered by AI for therapeutic breakthroughs. Founded in 2019 and based in Menlo Park, California, they have secured a significant $60.00M Series A investment in April 2022 from a notable group of investors including Anthos Capital, Initialized Capital, Breyer Capital, General Catalyst, Axial VC, and Presight Capital. The company specializes in indexing biological data into highly detailed maps of human disease, which is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Their cloud-based operating system enables researchers to organize, process, query, and analyze this data at scale, unlocking the ability to search biology in unprecedented ways. Enable Medicine collaborates with leading academic institutions and pharmaceutical companies globally, focusing on unmet needs in oncology and autoimmune diseases, thereby accelerating data generation, methods development, research insights, and high-impact publications. With an interdisciplinary team of scientists, engineers, researchers, and investors, Enable Medicine is dedicated to deciphering biological systems to make drug discovery, development, and patient care more deterministic. Their mission is to decode biology and improve patient treatment significantly, offering promising opportunities for investors seeking innovative solutions in the biotechnology and healthcare industries.